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recommendations for ‘safe’ alcohol consumption. The pur-
pose of this brief review is to update the knowledge on the 
combined effects of alcohol and obesity on the develop-
ment and progression of liver disease. Undoubtedly, alcohol 
and the metabolic syndrome appear as a dangerous mix, 
and there are important interactive effects of either condi-
tion with regard to crucial triggers of liver injury. 
 © 2016 S. Karger AG, Basel 
 Introduction 
 Chronic and excessive alcohol consumption can lead 
to the development of alcoholic liver disease (ALD), 
which is a critical health problem in many countries  [1] . 
The spectrum of liver injury ranges from steatosis and 
steatohepatitis to fibrosis, cirrhosis and hepatocellular 
carcinoma (HCC). Hepatocellular lipid accumulation is 
the first pathological step of ALD. Alcohol is predomi-
nantly metabolized in hepatocytes, and in the oxidation 
of ethanol to acetaldehyde, NAD is reduced to NADH, 
which promotes fatty acid synthesis while counteracting 
lipid catabolism, thus leading to fat accumulation in he-
patocytes  [2, 3] .
 More recently, the pathophysiological significance of 
hepatic lipid accumulation in the absence of significant 
alcohol consumption is increasingly recognized. Today, 
nonalcoholic fatty liver disease (NAFLD) is considered 
the most common cause of liver enzyme elevations in 
Western countries  [4] . In most cases, NAFLD is associ-
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 Abstract 
 Alcoholic liver disease (ALD) and nonalcoholic fatty liver dis-
ease (NAFLD) are the most frequent chronic liver disorders, 
and their advanced forms – alcoholic steatohepatitis and 
nonalcoholic steatohepatitis – are the most frequent condi-
tions leading to liver cirrhosis and hepatocellular carcinoma 
worldwide. NAFLD is considered as the hepatic manifesta-
tion of the metabolic syndrome. With the pandemic rise of 
obesity, the incidence of NAFLD is also further increasing, 
and considering the life style in modern societies, there is a 
significant overlap of (risk factors causing) NAFLD and (alco-
hol consumption predisposing for) ALD at least in Western 
countries. Epidemiological studies propose a causative link 
between chronic alcohol consumption and progressive liver 
disease in obese individuals. Furthermore, experimental 
studies indicate combined pathological effects of alcohol 
and obesity or fatty acid levels, respectively, on hepatocel-
lular lipid accumulation and injury as well as hepatic inflam-
mation, fibrosis and cancerogenesis. Notably, these com-
bined pathological effects are in part additive but partly 
even synergistic. And importantly, alcohol does already ex-
hibit synergistic pathological effects with obesity at moder-
ate doses. This indicates significant differences in the dose 
threshold for hepatotoxic alcohol effects in lean and obese 
subjects and herewith also has important implications for 
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ated with (components of) the metabolic syndrome, that 
is, central obesity and insulin resistance with resulting 
diabetes type 2, dyslipidemia and hypertension. There-
fore, NAFLD is regarded as the hepatic manifestation of 
the metabolic syndrome. Very similar as in ALD, NAFLD 
encompasses a wide range of pathological conditions 
from mild hepatic steatosis to steatohepatitis (a syndrome 
named non-alcoholic steatohepatitis (NASH)) with sig-
nificant necroinflammation and progressive fibrosis. In 
its advanced form, NASH is believed to account for a 
large fraction, if not entirely for what was previously 
termed ‘cryptogenic cirrhosis’ and also progresses to 
HCC in a significant number of cases  [5, 6] . Also, hepa-
tocellular fat accumulation is the first pathological step in 
NAFLD ( fig.  1 ). The metabolic syndrome is associated 
with increased levels of circulating free fatty acids (FFA) 
 [7] and the rate of hepatic FFA uptake is not regulated. 
Therefore, hepatic uptake of FFA is proportional to plas-
ma FFA concentrations and the predominant reason for 
hepatocellular fat accumulation in NAFLD  [8] .
 Epidemiology of Alcoholic and Non-Alcoholic Fatty 
Liver Disease 
 NAFLD reveals a drastically rising prevalence due to a 
lifestyle favoring the development of the metabolic syn-
drome, and today more than half of the adult population 
in most Western countries has already been found to be 
overweight. Furthermore, regardless of the precise defini-
tion of safe margins for the dose of daily alcohol con-
sumption, certainly, a 2-digit percentage of the popula-
tion in Western countries chronically consumes alcohol 
in amounts that predispose for ALD. Therefore, based on 
statistical numbers, there is a considerable overlap of in-
dividuals with both (components of) metabolic syndrome 
and chronic alcohol consumption. In addition, it has to 
be considered that in modern societies, people frequently 
drink alcohol with high caloric foods. Therefore, the 
overlap of obese and alcohol-drinking individuals is even 
larger than pure statistics would predict and it may con-
stitute even the vast majority of cases ( fig. 2 ). Certainly, a 
critical question is the definition of safe margins for the 
dose alcohol consumption. Dosis facit venenum, and cer-
tainly, this is also true for alcohol intake. However, the 
dose threshold of alcohol for its hepatotoxic effects de-
pends on a variety of factors including ethnicity and gen-
der  [9] . Guidelines from the European Association for the 
Study of the Liver and the American Association for the 
Study of the Liver recommend <30 g of alcohol per day in 
man and <20 g of alcohol per day in women  [9, 10] . Also, 
the Asian Pacific for the Study of the Liver guideline de-
fines different levels of daily alcohol consumption for 
men and women (<20 and 10 g, respectively) as ‘safe’. So 
far, body weight and obesity are not considered in guide-
lines. In fact, existing cutoff levels are used to differentiate 
ALD from NAFLD in most clinical trials.
 Combined Effects of Alcohol and Obesity on the 
Development and Progression of Liver Disease 
 Actually, it appears likely and plausible that the combi-
nation of 2 pathological mechanisms causes more harm 
than either of the 2 factors alone. Thus, it has been shown 
that pre-existing liver diseases such as hepatitis C infection 
 Fig. 1. ALD and NAFLD have very similar pathophysiological steps of disease progression, that is, hepatic ste-
atosis, inflammation and fibrosis. Progressive hepatic fibrosis may ultimately lead to cirrhosis, the major risk 
factor for HCC. 
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deteriorate with chronic alcohol ingestion  [11, 12] . Like-
wise, obesity and diabetes are independent risk factors for 
liver fibrosis in patients with chronic viral hepatitis infec-
tion  [13, 14] . A combined effect on the progression and 
development of liver injury seems even more probable in 
the case of alcohol and obesity since ALD and NAFLD re-
veal astonishing histopathological similarities  [15] .
 Indeed, several epidemiological studies suggest a 
strong causative link between the consumption of alco-
hol and progressive liver disease in individuals with high 
fat intake and/or diabetes. Combined effects appear to 
affect all pathophysiological steps of disease develop-
ment and progression, starting with hepatic steatosis. 
The DIONYSOS study was one of the first epidemiolog-
ical studies clearly showing combined effect of alcohol 
consumption and elevated body weight on hepatic ste-
atosis in a large cohort of subjects in Northern Italy  [16] . 
The prevalence of hepatic steatosis determined by ultra-
sonography was increased in subjects with a daily intake 
of >60 g of alcohol to 46% and in obese persons to 76% 
compared to lean controls that revealed hepatic steatosis 
only in 16% of cases. Still, in obese individuals drinking 
>60 g alcohol per day, steatosis was found in even 95% of 
individuals  [16] .
 Also, with regards to hepatocellular injury and inflam-
mation, a strong causative link has been found between 
alcohol consumption and obesity  [17, 18] . Of note, the 
likelihood of hepatic injury was higher at increasing body 
weight even when the levels of alcohol consumption were 
as low 28 g alcohol per day  [17] . Loomba et al.  [19] found 
that the odds for elevated serum transaminase levels in-
creased with higher body mass index (BMI) as well as 
each alcohol drinking level in a study with 2,364 individ-
uals in the US. OR was approximately 3 in obese people 
with no or only one drink per day and approximately 2 in 
lean individuals consuming 40 g alcohol per day or more. 
However, OR was nearly 9 in obese individuals drinking 
>40 g alcohol per day, showing a clear synergistic effect of 
alcohol and obesity on hepatocellular injury.
 Alcohol and obesity also appear as a critical associa-
tion for hepatic fibrosis and development of cirrhosis. In 
subjects with heavy alcohol consumption, obesity is an 
independent risk factor for the development of both acute 
alcohol-induced hepatitis and cirrhosis  [20, 21] . More-
over, Ekstedt et al.  [22] found an accelerated progression 
of fibrosis in patients with NAFLD who drank moderate 
(up to 140 g/week) amounts of alcohol. Liu et al.  [23] an-
alyzed more than 1 million middle aged women in the 
 Fig. 2. High frequency and high overlap of chronic alcohol con-
sumption and obesity. A significant percentage of the population 
in Western countries chronically drinks alcohol in amounts that 
predispose for ALD (symbolized by a red wine bottle). Further-
more, in many industrialized nations, almost half of the adult pop-
ulation are overweight or obese (symbolized by yellow color), and 
the majority of these individuals have NAFLD. Very frequently, 
excess alcohol and calorie intake coincide and therefore the fre-
quency of risky alcohol consumption in obese is even higher than 
in the general population (symbolized by grey color). 
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UK. Here, alcohol consumption of >150 g/week was 
found to increase the relative risk for cirrhosis approxi-
mately 3-fold while obesity (BMI >30) in individuals 
drinking <70 g alcohol/week did not significantly affect 
the risk for cirrhosis. However, in obese women drinking 
>150 g of alcohol/week, the relative cirrhosis risk in-
creased more than 6 fold.
 Lastly, there are strong epidemiological data showing 
a combined effect of alcohol and obesity on the risk of 
developing HCC. Ascha et al.  [24] found an increasing 
risk for HCC in patients with underlying NASH who con-
sumed alcohol in moderate amounts. In another study, 
Loomba et al.  [25] analyzed the relative HCC risk in 
23,712 Taiwanese residents. In this study, chronic alcohol 
consumption (>4 times per week for >1 year) did not sig-
nificantly affect HCC risk but obesity increased the risk 
by approximately 2 fold. Noteworthy, obesity and chron-
ic alcohol consumption together led to a 7-fold increase 
of HCC risk in this large study  [25] indicating a clear syn-
ergistic effect.
 Animal Models of Combined Effects of Alcohol and 
High Fat on Development and Progression of Liver 
Disease 
 Experimental studies have shown that obesity or feed-
ing a high fat diet (HFD), respectively, in combination 
with alcohol application accelerate hepatic steatosis, in-
flammation and fibrosis in mice and rats. These experi-
mental models also revealed mechanistic insights on how 
alcohol and obesity caused synergistic harm.
 Carmiel-Haggai et al.  [26] showed that short-term 
binge alcohol exposure increased apoptosis and liver in-
jury in obese rats compared to lean controls. In a study 
by Xu et al.  [27], moderate obesity induced by intragas-
tric overfeeding of a HFD and alcohol intake caused syn-
ergistic steatohepatitis in an alcohol dose-dependent 
manner. This was associated with increased fibrosis, in-
duction of inducible nitric oxide synthetase and reactive 
nitrogen species, that is, nitrosative stress. Wang et al. 
 [28] combined a genetic model for NASH, the leptin-
deficient, insulin-resistant Zucker rat by feeding ethanol 
containing Lieber-DeCarli diet and identified cyto-
chrome P-4502E1 induction and the generation of carci-
nogenic DNA lesions as exacerbating pathological forc-
es. Purohit et al.  [29] found that combined consumption 
of alcohol and a HFD significantly increased  SREBP-1 
and  FAS gene expressions in mice. Wang et al.  [30] in-
vestigated the effect of a rather low intake of ethanol 
(16% of total calories) on the progression of a HFD-in-
duced NASH model in Sprague–Dawley rats. They ob-
served an increased number of inflammatory foci and 
apoptosis due to the additional intake of ethanol, sug-
gesting that even moderate alcohol intake can augment 
hepatic inflammation and apoptosis in rodents with un-
derlying NASH.
 Also, we established an experimental murine model 
where we combined feeding a HFD, which results in 
(modest) weight gain with chronic alcohol administra-
tion in the drinking water resembling so-called ‘social 
drinking’  [31] . Under these experimental conditions, al-
cohol and HFD caused additive effects on hepatic steato-
sis and inflammation, while effects on hepatic fibrosis 
were clearly synergistic. The pronounced effect on hepat-
ic  fibrosis indicates that this phenomenon was not simply 
a result of timely preceding pathological effects but that 
alcohol and HFD cause (metabolic) changes that promote 
fibrogenesis via mechanisms independent of steatosis 
and inflammation.
 An in vitro Model of Combined Effects of Alcohol and 
Free Fatty on Hepatocytes 
 More recently, we have developed an in vitro model to 
study the combined effects of alcohol and FFA on pri-
mary human hepatocytes  [32] . To induce intracellular 
lipid accumulation, cells were incubated with FFA com-
plexed to albumin  [33] . Subsequently, steatotic and con-
trol hepatocytes were incubated with up to 50 m M alco-
hol. This alcohol concentration on its own revealed only 
minimal effects but significantly enhanced oleate-in-
duced lipogenesis and cellular triglyceride content com-
pared to control cells. Similarly, lipid peroxidation, oxi-
dative stress and pro-inflammatory gene expression were 
synergistically induced by alcohol and steatosis. Of note, 
the joint pathological effect of alcohol and cellular triglyc-
eride content were caused by synergistic induction of 
 CYP2E1 activity in our in vitro model. Generally, this cy-
tochrome P450 is known for its detrimental effects in 
ALD through free radical formation and lipid peroxida-
tion  [34, 35] . Therefore, pharmacological inhibition of 
CYP2E1 has emerged as strategy for treatment of alcohol-
induced liver injury  [34, 36] . Also, several studies identi-
fied the induction of cytochrome P4502E1 as a critical 
pathological factor in NAFLD. This cytochrome metabo-
lized both fatty acids and ethanol. When these substances 
are chronically present in large amounts, they induce the 
activity of this enzyme which is associated with the release 
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of free radicals. This reaction can cause lipid peroxidation 
and liver injury, and in vitro data indicate that these 
mechanisms are even synergistically enhanced in the 
presence of both alcohol and excessive FFA.
 Notably, alcohol and cellular steatosis also induced au-
tophagy in a synergistic manner in hepatocytes in vitro, 
and this was also mediated via CYP2E1  [32] . Further in-
duction of autophagy ameliorated the joint effects of al-
cohol and oleic acid on hepatocellular lipid accumulation 
and inflammatory gene expression while inhibition of au-
tophagy further enhanced the dual pathological effects.
 Autophagy is a highly conserved intracellular catabol-
ic pathway for the degradation of long-lived proteins and 
cytoplasmic organelles. The effects of ethanol on autoph-
agy are complex and only partly understood but it is be-
coming clear that autophagy serves a protective function 
against alcohol-induced liver injury  [37, 38] . Similarly, 
there is increasing evidence that autophagy also inhibits 
NAFLD progression  [39–41] .
 Certainly, the clinical relevancy of our in vitro find-
ings in hepatocytes has to be verified. Still, the CYP2E1-
mediated joint effects of alcohol- and oleate-induced ste-
atosis on autophagy indicate that alcohol induces not 
only pathological but also protective mechanisms in ste-
atotic hepatocytes via CYP2E1. Therefore, the manipula-
tion of  CYP2E1 may be a double-edged sword and war-
rant the exercise of caution in the pharmacological use of 
CYP2E1 inhibitors for the treatment of ALD in obese 
individuals. Furthermore, one may speculate whether in-
dividual factors tipping the balance on the one or the 
other side of detrimental or beneficial joint effects of al-
cohol and FFA account at least in part for the high varia-
tion in the clinical course of ALD. Only slight differences 
in the ratio of individual beneficial and detrimental fac-
tors may decide whether moderate alcohol consumption 
is protective or is causing harm in (non-alcoholic) fatty 
livers. Actually, there are some studies suggesting that 
moderate alcohol consumption might even be protective 
for patients with NAFLD  [42, 43] . Light to moderate al-
cohol consumption can lead to an improvement in pe-
ripheral insulin resistance, and herewith, may also have 
a protective effect against the development of diabetes 
and hepatic steatosis  [44–47] . However, these studies 
have to be reflected on with great caution. The border 
between safe or eventually even beneficial alcohol con-
sumption on the one side and dangerous and deleterious 
levels on the other side is extremely narrow and depends 
also on several confounding variables which are only in-
completely understood. Furthermore, one needs to be 
cautious because even if a certain level of drinking might 
protect against fatty liver disease, it may be harmful for 
other organs and tissues and may also increase the risk of 
certain cancers, such as breast or colorectal cancer  [48, 
49] .
 Extrahepatic Mechanisms Affecting Disease 
Progression in ALD and NAFLD 
 It has to be noted that both ALD and NAFLD occur in 
the context of a systemic disease, that is, (components of) 
the metabolic syndrome and chronic alcoholism. There-
fore, in addition to the liver, several other organs and bi-
ological functions can be affected. These pathological al-
terations can directly or indirectly promote inflammation 
and fibrosis in fatty liver  [50] . For instance, alcohol and 
obesity/diabetes lead to quantitative and qualitative 
changes of the microbiome and an impaired intestinal 
barrier, and these mechanisms are known to promote he-
patic inflammation, fibrosis and cancerogenesis  [51, 52] . 
One further example is (visceral) adipose tissue, in which 
secretion of adipokines is altered by both obesity and al-
cohol. Adiponectin, which is known to be hepatoprotec-
tive and anti-fibrotic, is reduced in individuals with obe-
sity or chronic alcohol consumption  [53–55] . In contrast, 
both chronic alcohol intake and obesity induce the ex-
pression of the profibrogenic adipokine leptin in adipose 
tissue  [56, 57] . There are several more extrahepatic sys-
temic processes and biological functions affected by both 
alcohol and the metabolic syndrome, making the rela-
tionship between ALD and NAFLD extremely complex. 
Accordingly, the mechanisms responsible for accelerated 
disease progression if both conditions coincide are most 
likely related to multiple factors.
 Confounding Dietary Factors Affecting Disease 
Progression in ALD and NAFLD 
 Experimental and epidemiological studies clearly indi-
cate that in addition to the quantity, the type of dietary fat 
also critically affects the pathogenesis of ALD  [58, 59] and 
NAFLD  [60, 61] . For instance, in vitro studies clearly 
show that saturated FFA cause more apoptosis in hepato-
cytes than unsaturated FFA  [62, 63] . Besides lipids, quan-
tity and quality of carbohydrates consumption have been 
shown to affect hepatic steatosis, inflammation and fibro-
sis in experimental models  [64, 65] . These findings are of 
particular relevancy in ALD where malnutrition is a fre-
quently observed problem  [66] .
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 Moreover, it becomes more and more evident that not 
only the amount of consumed alcohol but also the sub-
category of alcoholic beverage affects the development 
and progression liver disease. A recent study found that 
the ratio of the budget for healthy to that for unhealthy 
foods were highest for wine drinkers and lowest for beer 
drinkers  [67] . In this study, healthy foods included for 
instance coffee, and it has been shown by others that cof-
fee consumption has hepatoprotective effects  [68, 69] . On 
the other side, unhealthy foods were considered for in-
stance as soft drinks and saturated fatty acids, that is, di-
etary components well known to accelerate progression 
of liver disease  [63, 70] . Some studies have also suggested 
that a high percentage of red wine in the amount of alco-
hol consumed lowers the relative risk to develop (alco-
holic) liver cirrhosis  [71] . One explanation for this phe-
nomenon may be resveratrol, a polyphenol in grapes, 
which is also found in red wines  [72] . Several studies have 
demonstrated the protective effects of resveratrol in ex-
perimental models of liver injury in animals  [73–75] . 
More recent studies show that beer also contains sub-
stances that protect from liver damage  [76] . Furthermore, 
experimental studies revealed that hop ingredients such 
as xanthohumol or iso-alpha acids inhibit hepatic steato-
sis, inflammation, fibrosis and hepatocarcinogenesis 
 [77] . Moreover, these hop ingredients have been shown 
to beneficially affect the metabolic syndrome  [77] and it 
has been shown already in patients with prediabetes that 
doses of iso-alpha acids as low as 1.5 mg/kg daily im-
proved insulin resistance and reduced body weight  [78] . 
This dose corresponds to a beer consumption of approx-
imately 1–6 liter depending on the type of beer  [79] . This 
means that with alcohol consumption of approximately 
40 g/day in the form of beers with high content of iso-
alpha acids, some beneficial effects on insulin resistance 
and body weight could be achieved. Together, the avail-
able data show that not only the amount of alcohol and 
calorie intake but also the type of food and alcoholic bev-
erages affect ALD and NAFLD, which further contributes 
to the complexity of the interaction between alcohol and 
obesity in (chronic) liver disease.
 Conclusion 
 Alcoholic and non-alcoholic liver fatty liver disease are 
the most frequent liver diseases worldwide, and one needs 
to consider that both conditions overlap in a significant 
number of patients. There is unequivocal epidemiological 
and experimental evidence that alcohol and (components 
of) the metabolic syndrome exhibit combined effects on 
the development and progression of liver injury, which 
are in part additive and partly even synergistic. Conse-
quently, these combined effects have a major impact on 
the dose threshold for hepatotoxic alcohol effects, that is, 
safety levels for ‘social drinking’ and guideline recommen-
dations for ‘safe’ alcohol consumption. Today, practically 
all guideline recommendations define different threshold 
levels for hepatotoxic alcohol in man and woman. Avail-
able data strongly suggest that in addition to gender, the 
presence of overweight and obesity should be considered 
for defining safe alcohol levels. Obese individuals should 
adhere to lower amounts of regular alcohol consumption 
than lean subjects, and those who drink within safe mar-
gins should take care to not become overweight.
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